Geraniol Insect Repellents and the EU BPR: What's Changing in 2026–2027

Update, March 2026: The transitional period for geraniol-containing biocidal products in the EU expires on 30 April 2026 — six weeks from the date of this article. If you distribute or sell insect repellents or insecticides containing geraniol in the EU, this article is the most important thing you will read this month.

What just happened: the July 2025 ECHA decision

On 2 July 2025, the European Chemicals Agency (ECHA) published an updated list of active substances in the EU Biocidal Products Regulation (BPR) review programme. The update confirmed something that had been anticipated in regulatory circles for some time: no company or industry consortium submitted a notification to support the continued authorisation of geraniol for Product Type 18 (insecticides and acaricides) or Product Type 19 (repellents and attractants).

Under the BPR framework, when no party submits support for an active substance's continued approval, ECHA formally classifies the substance as "unsupported" for those product types. This classification triggers a formal non-approval decision by the European Commission — meaning geraniol will not be permitted as an active ingredient in EU-registered insecticides or repellents going forward.

ECHA's own published status for geraniol in the BPR programme is now listed as: "Commission decision — participant withdrawal."

This is not a proposal or a risk. It is a confirmed regulatory outcome.

The timeline: what happens when

Date	Event
2 July 2025	ECHA publishes updated BPR review list. Geraniol confirmed unsupported for PT18 and PT19. No notifier submitted support by the required deadline.
Sept–Oct 2025	ANSES (French biocide authority) confirms at the Biocide Congress in Lyon that geraniol is no longer supported under the EU Biocidal Active Substance Review Programme.
30 April 2026 ⚠️	Geraniol's current BPR approval extension expires. This is the current confirmed end date for the transitional period. Products on the market may enter a grace period, but no new products may be placed on the market after the Commission's non-approval decision.
Post April 2026	European Commission issues formal non-approval decision. Each EU Member State then determines its own withdrawal timeline for products already in the market. Placing new geraniol-based PT18/PT19 biocidal products on the EU market becomes prohibited.

The exact grace period for products already on shelves will vary by Member State. Germany, given its historically strict national application of BPR rules, is expected to act on the shorter end of that timeline.

What this means in plain terms

Let's be direct about what these regulatory steps mean for the market:

New geraniol-based insect repellents and insecticides cannot be placed on the EU market once the Commission issues its non-approval decision. Companies cannot register new products, expand existing ranges, or reformulate using geraniol as the active substance.

Existing products have a finite shelf life in the EU. Products currently authorised under transitional provisions will be subject to withdrawal once the grace period ends in each Member State. The clock is running.

Retailers and distributors face a portfolio risk. Products you carry today may not be reorderable in the same formulation once the transitional period ends. If your current supplier has not confirmed a reformulation strategy, you need that conversation now.

The "natural" label does not confer regulatory protection. Geraniol is derived from rose oil, citronella, and other botanicals. Many products containing it have been marketed as natural, plant-based, or eco-friendly alternatives to synthetic repellents. This does not exempt them from BPR requirements. The regulatory outcome is the same regardless of origin.

Why geraniol lost support — the real reasons

The fact that no company or consortium stepped forward to support geraniol's continued approval is significant. Submitting an active substance dossier for BPR approval is a multi-year, multi-million euro process. The industry effectively voted with its feet: the investment was not worth making.

Several factors contributed to this:

Poor efficacy-to-duration ratio. Independent field studies consistently show geraniol provides repellency for under two hours — often under one hour under warm, outdoor conditions. Under BPR, products must demonstrate adequate efficacy for their claimed use. A repellent that requires reapplication every 45 minutes has a weak regulatory position when compared to substances offering hours-long or weeks-long protection.

Skin sensitisation profile. Geraniol is a documented skin sensitiser and is listed among the 26 fragrance allergens that must be declared on cosmetic product labels under EU Cosmetics Regulation. For a biocidal product — applied repeatedly, often to surfaces in living spaces — this sensitisation profile created a difficult safety dossier to defend under BPR's stringent human health assessment criteria.

Aquatic toxicity concerns. Geraniol has been shown to have moderate-to-significant aquatic toxicity, particularly to invertebrates. This is a standard assessment area under BPR's environmental risk criteria, and the data was not favourable enough to make the dossier straightforward.

The combined picture was a substance that was expensive to defend, with a weak efficacy profile and ongoing safety questions. The rational industry decision was to let the approval lapse.

What also changed: lavandin oil (PT19)

Geraniol is not alone. The same ECHA update and subsequent Biocide Congress announcement also flagged lavandin oil (lavender/Lavandula hybrida extract) for PT19. While a notifier deadline of 26 August 2026 remains open for lavandin — meaning a company could still step forward to support it — the signal is clear: the "natural botanical" active substance category for repellents is under broad regulatory pressure in the EU.

Distributors and brand owners who have built product lines around plant-derived actives should audit their entire portfolio, not just geraniol-specific SKUs.

The compliant alternatives: what actually works and has regulatory stability

The good news for the market is that BPR-approved alternatives exist, with strong safety profiles, proven efficacy, and long-term regulatory stability. The two primary options relevant to the insect repellent market are:

Icaridin (picaridin / KBR 3023)

Icaridin is the World Health Organisation's recommended active ingredient for protection against mosquitoes carrying malaria, dengue, chikungunya, and Zika. It is BPR-approved for PT19, has a well-established safety profile, and is not a known skin sensitiser at standard use concentrations.

Crucially, its efficacy profile is fundamentally different from geraniol's. Skin-applied icaridin formulations provide 4–8 hours of protection. Surface-applied icaridin formulations using controlled-release delivery — Repeltec — provide protection for up to 12 weeks from a single application.

DEET (N,N-Diethyl-meta-toluamide)

DEET remains BPR-approved and highly effective. However, it faces consumer acceptance challenges in Northern and Western Europe, and carries restrictions for use with young children and during pregnancy. It is unlikely to be the direction for new product development in the consumer segment.

IR3535

IR3535 is BPR-approved and effective in skin-applied formulations. It does not offer meaningful surface repellency and has limited duration compared to modern controlled-release icaridin formulations.

How Affix Labs and Repeltec fit into this picture

Repeltec is the only surface applied product built on icaridin, delivered through Affix Labs' patented water-based controlled-release platform. We are not affected by the geraniol phase-out. Our regulatory position is stable, and our product is available today.

The Affix Labs platform was specifically designed to address what was wrong with existing repellent technologies — including short-duration naturals like geraniol and citronella. Our controlled-release system encapsulates icaridin in a biodegradable controlled release system the active ingredient slowly over weeks, not hours. The formulation is more than 70% water, uses no harsh organic solvents, and produces no microplastic residues in the release mechanism.

The environmental numbers that result from this approach are significant:

• Repeltec's aquatic toxicity (LC50, Daphnia) is up to 100 times lower than geraniol's

• The active ingredient persists in the environment for a fraction of the time compared to pyrethroids

• Because a single application lasts 12 weeks, the total active ingredient used over a season is dramatically lower than daily-application alternatives

  
  

This means Repeltec performs better on the same metrics that caused geraniol to fail its BPR dossier — while delivering a significantly longer protection window.

For distributors: the "Powered by Affix Labs" white-label programme

If you are currently distributing geraniol-based repellent products in the EU and need a compliant replacement you can sell under your own brand, this is the right conversation to start now.

Affix Labs offers white-label supply under our "Powered by Affix Labs" programme. Partners receive:

• BPR-compliant formulation with full regulatory documentation

• Custom labelling and packaging under your brand

• Technical and regulatory support for national registration where required

• Proven product with commercial track record across Europe, South Africa, and Southeast Asia

  
  

We supply existing distributors in multiple markets and have capacity for new partners. Sample orders are available via affixlabs.com/sample. For partnership discussions: info@affixlabs.com with subject line "Geraniol replacement — white-label enquiry".

What to do in the next 30 days

Given that the current transitional period ends 30 April 2026, the practical checklist for distributors and brand owners is:

1. Audit your current portfolio for geraniol-containing PT18 and PT19 products. Check every active substance declaration on every biocidal product you sell or distribute in the EU. Include products marketed as "natural," "plant-based," or "citronella-derived" — geraniol is present in many of these under various names (geraniol, geranyl acetate, rose oil concentrate).

2. Contact your current suppliers to confirm their reformulation status. If your supplier does not have a confirmed non-geraniol reformulation in place, their product range will have no legal pathway in the EU after the grace period.

3. Request samples and regulatory documentation from alternative suppliers. Procurement cycles and national registration processes take time. Starting now gives you options; starting in May does not.

4. Monitor your national competent authority for the local grace period timeline. Germany (BfR/UBA), France (ANSES), and the Netherlands (Ctgb) will each set their own withdrawal timelines. Subscribe to their update channels.

5. Brief your retail buyers and key accounts. If you supply retailers, they need to know the regulatory situation for their buying decisions in H2 2026 and beyond.

Summary

Geraniol lost its EU BPR support on 2 July 2025, when ECHA confirmed no notifier had submitted support for its continued approval in PT18 (insecticides) or PT19 (repellents). Its current approval extension expires on 30 April 2026. A formal European Commission non-approval decision follows, after which placing new geraniol-based biocidal insecticides and repellents on the EU market becomes prohibited.

The phase-out is not a surprise to those who track ECHA's review programme — but its implications have not yet reached the mainstream retail and distribution conversation. That gap is closing fast.

Icaridin-based alternatives with BPR approval and proven efficacy profiles exist today. Repeltec, produced by Affix Labs using a patented controlled-release platform, is one such alternative and is available for white-label supply now.

Key Source referenced in this article:

• ECHA BPR Active Substance Review Programme — updated list published 2 July 2025